In brief: A new breast cancer indication for sacituzumab govitecan (Trodelvy)

Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-e44. doi: 10.58347/tml.2023.1671g.
No abstract available

Keywords: Trodelvy; adverse effects; breast cancer; capecitabine; dosage; drug interactions; efficacy; eribulin; gemcitabine; lactation; pregnancy; sacituzumab govitecan; safety; vinorelbine.

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Breast Neoplasms* / drug therapy
  • Camptothecin
  • Female
  • Humans
  • Immunoconjugates*

Substances

  • sacituzumab govitecan
  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • Camptothecin